The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy
Wu, X.; Zhou, F.; Ji, X.; Ren, K.; Shan, Y.; Mao, X.; Fen, Y.; Chen, R.; Ding, H.; Fu, X.
Future Oncology 13(29): 2691-2696
2017
ISSN/ISBN: 1744-8301
PMID: 28972404
DOI: 10.2217/fon-2017-0426
Accession: 060376255
We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC). We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response. We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan-Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy. MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.